

# John W Barrett

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/8956456/john-w-barrett-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

80  
papers

3,061  
citations

28  
h-index

54  
g-index

84  
ext. papers

3,432  
ext. citations

7  
avg, IF

4.44  
L-index

#	Paper	IF	Citations
80	Introduction and expression of PIK3CA in a papillary thyroid cancer BRAF cell line leads to a dedifferentiated aggressive phenotype.. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , <b>2022</b> , 51, 7	5.4	1
79	All HPV-negative head and neck cancers are not the same: Analysis of the TCGA dataset reveals that anatomical sites have distinct mutation, transcriptome, hypoxia, and tumor microenvironment profiles. <i>Oral Oncology</i> , <b>2021</b> , 116, 105260	4.4	5
78	Low expression of NSD1, NSD2, and NSD3 define a subset of human papillomavirus-positive oral squamous carcinomas with unfavorable prognosis. <i>Infectious Agents and Cancer</i> , <b>2021</b> , 16, 13	3.5	2
77	Detection of Circulating Tumor DNA in Patients with Thyroid Nodules. <i>International Journal of Endocrinology</i> , <b>2021</b> , 2021, 8909224	2.7	0
76	DIY: Visualizing the immune landscape of tumors using transcriptome and methylome data. <i>Methods in Enzymology</i> , <b>2020</b> , 636, 49-76	1.7	1
75	Sex disparities in head & neck cancer driver genes: An analysis of the TCGA dataset. <i>Oral Oncology</i> , <b>2020</b> , 104, 104614	4.4	7
74	Survival-Associated Metabolic Genes in Human Papillomavirus-Positive Head and Neck Cancers. <i>Cancers</i> , <b>2020</b> , 12,	6.6	15
73	Analysis of the TCGA Dataset Reveals that Subsites of Laryngeal Squamous Cell Carcinoma are Molecularly Distinct. <i>Cancers</i> , <b>2020</b> , 13,	6.6	1
72	Spleen tyrosine kinase expression is correlated with human papillomavirus in head and neck cancer. <i>Oral Oncology</i> , <b>2020</b> , 101, 104529	4.4	4
71	Chromosome 3p loss in the progression and prognosis of head and neck cancer. <i>Oral Oncology</i> , <b>2020</b> , 109, 104944	4.4	3
70	TAM family receptors in conjunction with MAPK signalling are involved in acquired resistance to PI3K inhibition in head and neck squamous cell carcinoma. <i>Journal of Experimental and Clinical Cancer Research</i> , <b>2020</b> , 39, 217	12.8	5
69	Flavopiridol causes cell cycle inhibition and demonstrates anti-cancer activity in anaplastic thyroid cancer models. <i>PLoS ONE</i> , <b>2020</b> , 15, e0239315	3.7	3
68	Mutational analysis of head and neck squamous cell carcinoma stratified by smoking status. <i>JCI Insight</i> , <b>2019</b> , 4,	9.9	15
67	High Level Expression of MHC-II in HPV+ Head and Neck Cancers Suggests that Tumor Epithelial Cells Serve an Important Role as Accessory Antigen Presenting Cells. <i>Cancers</i> , <b>2019</b> , 11,	6.6	11
66	Disruption of the RICTOR/mTORC2 complex enhances the response of head and neck squamous cell carcinoma cells to PI3K inhibition. <i>Molecular Oncology</i> , <b>2019</b> , 13, 2160-2177	7.9	13
65	Genomic and human papillomavirus profiling of an oral cancer cohort identifies TP53 as a predictor of overall survival. <i>Cancers of the Head &amp; Neck</i> , <b>2019</b> , 4, 5	5.9	6
64	A controlled trial of HNSCC patient-derived xenografts reveals broad efficacy of PI3K inhibition in controlling tumor growth. <i>International Journal of Cancer</i> , <b>2019</b> , 145, 2100-2106	7.5	16

63	Treatment-naïve HPV+ head and neck cancers display a T-cell-inflamed phenotype distinct from their HPV- counterparts that has implications for immunotherapy. <i>Oncoimmunology</i> , <b>2018</b> , 7, e1498439	7.2	68
62	ERK-TSC2 signalling in constitutively-active HRAS mutant HNSCC cells promotes resistance to PI3K inhibition. <i>Oral Oncology</i> , <b>2018</b> , 84, 95-103	4.4	19
61	The prevalence of human papillomavirus in pediatric tonsils: a systematic review of the literature. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , <b>2018</b> , 47, 8	5.4	7
60	High-throughput testing in head and neck squamous cell carcinoma identifies agents with preferential activity in human papillomavirus-positive or negative cell lines. <i>Oncotarget</i> , <b>2018</b> , 9, 26064-26071	3.3	11
59	Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models. <i>PLoS ONE</i> , <b>2018</b> , 13, e02073152	3.5	12
58	Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas. <i>Nature Genetics</i> , <b>2017</b> , 49, 180-185	36.3	132
57	Analysis of Class I Major Histocompatibility Complex Gene Transcription in Human Tumors Caused by Human Papillomavirus Infection. <i>Viruses</i> , <b>2017</b> , 9,	6.2	17
56	Repurposing Albendazole: new potential as a chemotherapeutic agent with preferential activity against HPV-negative head and neck squamous cell cancer. <i>Oncotarget</i> , <b>2017</b> , 8, 71512-71519	3.3	18
55	Human papillomavirus dysregulates the cellular apparatus controlling the methylation status of H3K27 in different human cancers to consistently alter gene expression regardless of tissue of origin. <i>Oncotarget</i> , <b>2017</b> , 8, 72564-72576	3.3	18
54	Feasibility of Targeting PIK3CA Mutations in Head and Neck Squamous Cell Carcinoma. <i>Pathology and Oncology Research</i> , <b>2016</b> , 22, 35-40	2.6	3
53	Evidence for differential viral oncolytic efficacy in an in vitro model of epithelial ovarian cancer metastasis. <i>Molecular Therapy - Oncolytics</i> , <b>2015</b> , 2, 15013	6.4	28
52	Vaccinia virus outperforms a panel of other poxviruses as a potent oncolytic agent for the control of head and neck squamous cell carcinoma cell lines. <i>Intervirology</i> , <b>2014</b> , 57, 17-22	2.5	7
51	The control of anaplastic thyroid carcinoma cell lines by oncolytic poxviruses. <i>Virus Research</i> , <b>2014</b> , 190, 53-9	6.4	7
50	Variable expression of the forgotten oncogene E5 in HPV-positive oropharyngeal cancer. <i>Journal of Clinical Virology</i> , <b>2014</b> , 61, 94-100	14.5	19
49	Genomically driven precision medicine to improve outcomes in anaplastic thyroid cancer. <i>Journal of Oncology</i> , <b>2014</b> , 2014, 936285	4.5	19
48	Exploiting high-throughput cell line drug screening studies to identify candidate therapeutic agents in head and neck cancer. <i>BMC Pharmacology &amp; Toxicology</i> , <b>2014</b> , 15, 66	2.6	21
47	Does HPV type affect outcome in oropharyngeal cancer?. <i>Journal of Otolaryngology - Head and Neck Surgery</i> , <b>2013</b> , 42, 9	5.4	41
46	High frequency of activating PIK3CA mutations in human papillomavirus-positive oropharyngeal cancer. <i>JAMA Otolaryngology - Head and Neck Surgery</i> , <b>2013</b> , 139, 617-22	3.9	53

45	The tanapoxvirus 15L protein is a virus-encoded neuregulin that promotes viral replication in human endothelial cells. <i>Journal of Virology</i> , <b>2013</b> , 87, 3018-26	6.6	7
44	Role of FDG-PET as a biological marker for predicting the hypoxic status of tongue cancer. <i>Head and Neck</i> , <b>2012</b> , 34, 1395-402	4.2	47
43	Frequent mutations in TP53 and CDKN2A found by next-generation sequencing of head and neck cancer cell lines. <i>JAMA Otolaryngology</i> , <b>2012</b> , 138, 732-9		34
42	Central auditory processing impairment in patients with temporal lobe epilepsy. <i>Epilepsy and Behavior</i> , <b>2011</b> , 20, 370-4	3.2	23
41	Potent oncolytic activity of raccoonpox virus in the absence of natural pathogenicity. <i>Molecular Therapy</i> , <b>2010</b> , 18, 896-902	11.7	25
40	Clinical value of office-based endoscopic incisional biopsy in diagnosis of nasal cavity masses. <i>Otolaryngology - Head and Neck Surgery</i> , <b>2010</b> , 143, 341-7	5.5	29
39	Myxoma and vaccinia viruses exploit different mechanisms to enter and infect human cancer cells. <i>Virology</i> , <b>2010</b> , 401, 266-79	3.6	23
38	The extracellular domain of CD11d regulates its cell surface expression. <i>Journal of Leukocyte Biology</i> , <b>2009</b> , 86, 851-62	6.5	4
37	Induction of alpha/beta interferon by myxoma virus is selectively abrogated when primary mouse embryo fibroblasts become immortalized. <i>Journal of Virology</i> , <b>2009</b> , 83, 5928-32	6.6	16
36	Myxoma virus selectively disrupts type I interferon signaling in primary human fibroblasts by blocking the activation of the Janus kinase Tyk2. <i>Virology</i> , <b>2009</b> , 387, 136-46	3.6	13
35	Myxoma virus M130R is a novel virulence factor required for lethal myxomatosis in rabbits. <i>Virus Research</i> , <b>2009</b> , 144, 258-65	6.4	10
34	Yaba monkey tumor virus encodes a functional inhibitor of interleukin-18. <i>Journal of Virology</i> , <b>2008</b> , 82, 522-8	6.6	16
33	Oncolytic efficacy of recombinant vesicular stomatitis virus and myxoma virus in experimental models of rhabdoid tumors. <i>Clinical Cancer Research</i> , <b>2008</b> , 14, 1218-27	12.9	42
32	Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. <i>Molecular Therapy</i> , <b>2008</b> , 16, 52-9	11.7	60
31	RIG-I mediates the co-induction of tumor necrosis factor and type I interferon elicited by myxoma virus in primary human macrophages. <i>PLoS Pathogens</i> , <b>2008</b> , 4, e1000099	7.6	72
30	Origin and Evolution of Poxviruses <b>2008</b> , 431-446		2
29	Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. <i>Journal of NeuroVirology</i> , <b>2007</b> , 13, 549-60	3.9	29
28	Myxoma virus M063R is a host range gene essential for virus replication in rabbit cells. <i>Virology</i> , <b>2007</b> , 361, 123-32	3.6	24

27	Tropism of Tanapox virus infection in primary human cells. <i>Virology</i> , <b>2007</b> , 368, 32-40	3.6	10
26	M-T5, the ankyrin repeat, host range protein of myxoma virus, activates Akt and can be functionally replaced by cellular PIKE-A. <i>Journal of Virology</i> , <b>2007</b> , 81, 2340-8	6.6	35
25	M135R is a novel cell surface virulence factor of myxoma virus. <i>Journal of Virology</i> , <b>2007</b> , 81, 106-14	6.6	27
24	Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. <i>Cancer Research</i> , <b>2007</b> , 67, 8818-27	10.1	88
23	Oncolytic virotherapy synergism with signaling inhibitors: Rapamycin increases myxoma virus tropism for human tumor cells. <i>Journal of Virology</i> , <b>2007</b> , 81, 1251-60	6.6	66
22	Myxoma virus expressing human interleukin-12 does not induce myxomatosis in European rabbits. <i>Journal of Virology</i> , <b>2007</b> , 81, 12704-8	6.6	8
21	Comparative genetic analysis of genomic DNA sequences of two human isolates of Tanapox virus. <i>Virus Research</i> , <b>2007</b> , 129, 11-25	6.4	16
20	Genus Leporipoxvirus <b>2007</b> , 183-201		2
19	Variation in ligand binding specificities of a novel class of poxvirus-encoded tumor necrosis factor-binding protein. <i>Journal of Biological Chemistry</i> , <b>2006</b> , 281, 22517-26	5.4	13
18	Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2006</b> , 103, 4640-5	11.5	146
17	Poxvirus tumor necrosis factor receptor (TNFR)-like T2 proteins contain a conserved preligand assembly domain that inhibits cellular TNFR1-induced cell death. <i>Journal of Virology</i> , <b>2006</b> , 80, 9300-9	6.6	34
16	Myxoma virus M11L blocks apoptosis through inhibition of conformational activation of Bax at the mitochondria. <i>Journal of Virology</i> , <b>2006</b> , 80, 1140-51	6.6	56
15	Raccoonpox in a Canadian cat. <i>Veterinary Dermatology</i> , <b>2006</b> , 17, 443-8	1.8	8
14	Optimization of codon usage of poxvirus genes allows for improved transient expression in mammalian cells. <i>Virus Genes</i> , <b>2006</b> , 33, 15-26	2.3	24
13	Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. <i>Cancer Research</i> , <b>2005</b> , 65, 9982-9990	10.1	131
12	A poxvirus-encoded pyrin domain protein interacts with ASC-1 to inhibit host inflammatory and apoptotic responses to infection. <i>Immunity</i> , <b>2005</b> , 23, 587-98	32.3	193
11	Myxoma virus M141R expresses a viral CD200 (vOX-2) that is responsible for down-regulation of macrophage and T-cell activation in vivo. <i>Journal of Virology</i> , <b>2005</b> , 79, 6052-67	6.6	67
10	Myxoma virus M11L prevents apoptosis through constitutive interaction with Bak. <i>Journal of Virology</i> , <b>2004</b> , 78, 7097-111	6.6	76

9	Disruption of Erk-dependent type I interferon induction breaks the myxoma virus species barrier. <i>Nature Immunology</i> , <b>2004</b> , 5, 1266-74	19.1	145
8	A secreted high-affinity inhibitor of human TNF from Tanapox virus. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2003</b> , 100, 4831-6	11.5	54
7	Complete genomic sequence and comparative analysis of the tumorigenic poxvirus Yaba monkey tumor virus. <i>Journal of Virology</i> , <b>2003</b> , 77, 13335-47	6.6	45
6	Poxviruses and immune evasion. <i>Annual Review of Immunology</i> , <b>2003</b> , 21, 377-423	34.7	493
5	Role of the serine-threonine kinase PAK-1 in myxoma virus replication. <i>Journal of Virology</i> , <b>2003</b> , 77, 5876-88	6.8	68
4	Immunomodulatory proteins of myxoma virus. <i>Seminars in Immunology</i> , <b>2001</b> , 13, 73-84	10.7	54
3	Modulating chemokines: more lessons from viruses. <i>Trends in Immunology</i> , <b>2000</b> , 21, 100-6		102
2	Characterization of the nucleoside triphosphate phosphohydrolase I gene from the <i>Choristoneura fumiferana</i> entomopoxvirus. <i>Virus Research</i> , <b>1998</b> , 56, 93-105	6.4	2
1	Cloning, sequencing and transcriptional analysis of the <i>Choristoneura fumiferana</i> entomopoxvirus spheroidin gene. <i>Virus Research</i> , <b>1997</b> , 47, 143-54	6.4	11